---
layout: default
title: Pegvisomant
parent: Model Prediction Only (L5)
nav_order: 710
evidence_level: L5
indication_count: 10
---

# Pegvisomant
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Pegvisomant: From Acromegaly to Borderline Ovarian Serous Tumor

## One-Sentence Summary

Pegvisomant (brand name SOMAVERT) is a growth hormone receptor antagonist, originally used to treat acromegaly.
The TxGNN model predicts it may be effective for **borderline ovarian serous tumor**, but **0 clinical trials** and **0 publications** currently support this direction. The prediction rests on the model score alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Acromegaly (general knowledge of the product; not stated in the provided license records) |
| Predicted New Indication | Borderline ovarian serous tumor |
| TxGNN Prediction Score | 98.63% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 5 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the input. Pegvisomant is a growth hormone receptor antagonist that lowers IGF-1. Its efficacy in acromegaly is established, and mechanistically it might be applicable to tumors whose growth depends on GH/IGF-1 signaling.

For ovarian epithelial tumors, a GH/IGF-1 hypothesis is plausible but unverified. No preclinical, clinical or literature evidence was provided to support it, so the high score (98.63%) should be read as a model output, not as proof of efficacy.

The other top-10 predictions are mostly benign or borderline ovarian tumors, all with scores around 98.5%. Two predictions have no plausible link to GH receptor antagonism:
- **Pyelonephritis** is a bacterial infection treated with antimicrobials.
- **Aleukemic mast cell leukemia** is typically driven by KIT mutations.

These two are likely knowledge-graph artifacts.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2448858 | SOMAVERT |
| 2272199 | SOMAVERT |
| 2272210 | SOMAVERT |
| 2272202 | SOMAVERT |
| 2448831 | SOMAVERT |

## Safety Considerations

Please refer to the package insert for safety information.

No drug interaction records were found in the queried database.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no supporting clinical trials or literature (Evidence Level L5), and the GH/IGF-1 link to ovarian tumors is speculative. The Health Canada package insert is also missing, so safety screening cannot proceed.

**To proceed, the following is needed:**
- Health Canada package insert (warnings and contraindications), a blocking gap
- Mechanism of action data from DrugBank
- Preclinical or clinical evidence linking GH/IGF-1 signaling to ovarian serous borderline tumors
- Assessment of route compatibility and similarity to the original indication

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

